The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease

Irene E. Zohn,1 Ivana De Domenico,2 Andrew Pollock,1 Diane McVey Ward,2 Jessica F. Goodman,1 Xiayun Liang,3 Amaru J. Sanchez,1 Lee Niswander,1 and Jerry Kaplan2

1Howard Hughes Medical Institute, Department of Pediatrics, Section of Developmental Biology, University of Colorado at Denver and Health Sciences Center, Aurora; 2Department of Pathology, School of Medicine, University of Utah, Salt Lake City; 3Department of Pathology, University of Colorado Health Sciences Center, Denver

Ferroportin disease is caused by mutation of one allele of the iron exporter ferroportin (Fpn/IREG1/Slc40a1/MTP1). All reported human mutations are missense mutations and heterozygous null mutations in mouse Fpn do not recapitulate the human disease. Here we describe the flatiron (ffe) mouse with a missense mutation (H32R) in Fpn that affects its localization and iron export activity. Similar to human patients with classic ferroportin disease, heterozygous ffe/+ mice present with iron loading of Kupffer cells, high serum ferritin, and low transferrin saturation. In macrophages isolated from ffe/+ heterozygous mice and through the use of Fpn plasmids with the ffe mutation, we show that Fpnffe acts as a dominant negative, preventing wild-type Fpn from localizing on the cell surface and transporting iron. These results demonstrate that mutations in Fpn resulting in protein mislocalization act in a dominant-negative fashion to cause disease, and the Fpnffe mouse represents the first mouse model of ferroportin disease. (Blood. 2007;109:4174-4180)

© 2007 by The American Society of Hematology

Introduction

Hereditary hemochromatosis is a common disorder in humans, characterized by iron overload resulting in tissue injury and ultimately organ failure. Typically, hemochromatosis exhibits an autosomal-recessive pattern of inheritance and is associated with mutations in HFE, hemojuelin, hepcidin, or transferrin receptor 2.1,2 Targeted deletion of these genes in the mouse results in hemochromatosis, providing mouse models for most forms of the disease. Hemochromatosis type IV, also referred to as ferroportin (Fpn) disease, results from mutations in the iron transporter ferroportin. Fpn is the only known iron exporter in mammalian cells and is present on the surface of macrophages, intestinal enterocytes, hepatocytes, and placental cells.3,5 The level of cell surface Fpn is regulated by its interaction with hepcidin, a peptide secreted by the liver in response to iron stores and inflammation. Hepcidin binds to Fpn, inducing its internalization and degradation, thus regulating the export of iron from cells to plasma.6

Mutations in Fpn lead to iron-overload disease but, in contrast to other forms of hereditary hemochromatosis, ferroportin disease exhibits an autosomal-dominant pattern of inheritance.7 The disorder has different presentations depending on the Fpn mutation. Mutations leading to Fpn that is not internalized by hepcidin result in iron accumulation in hepatocytes and high transferrin saturation.8,9 Mutations leading to Fpn that is not appropriately targeted to the cell surface result in iron accumulation in Kupffer cells and low transferrin saturation.9,11 The mechanism by which the disease mutations exert a dominant effect is unclear. Some groups that study the disease suggest that it results from haploinsufficiency,10,12 whereas others suggest that the disorder results from a dominant-negative effect of the mutant allele.9,13 Importantly, all human mutations are missense mutations and mice that are heterozygous for a targeted deletion of Fpn do not show the disease.14 Treatment for hemochromatosis aims to decrease iron load by repeated phlebotomy and this treatment works well for most patients. Many patients with ferroportin disease, however, become anemic with phlebotomy, highlighting the need for a mouse model to develop better treatments.

We report here on a missense mutation in mouse Fpn that results in a disorder that is identical to classic human ferroportin disease. We show that macrophages isolated from mutant mice have no Fpn on their cell surface and that expression of Fpn constructs containing the missense mutation (H32R) affects the behavior of wild-type Fpn. These results show that Fpn disease is due to a dominant-negative effect of the mutant allele and provide the first mouse model for this disorder.

Materials and methods

Generation of mutant mice and identification of Fpn mutation

The ffe mouse line was identified in a screen for recessive ethyl nitrosourea (ENU)–induced mutations that cause morphologic abnormalities at embryonic day (E) 12.5.15-17 The ffe mutation was generated on a C57BL/6J genetic background and backcrossed to C3H/HeJ or 129/SvJ. In a mapping cross of 1078 opportunities for recombination, ffe was mapped between Massachusetts Institute of Technology (mit) simple sequence-length polymorphism (SSLP) markers D1mit213 and D1mit528. For high-resolution mapping, additional polymorphic DNA markers were generated based on nucleotide repeat sequences. D1sk4-l: CCTCTACCAGCCTATTTCTCT;
transfection, the cells were trypsinized and plated onto 35-mm plates with Oligofectamine reagent (Invitrogen) as described. At 24 hours after phages were transfected with siRNAs at concentrations up to 100 nM using obtained from Dharmacon (Lafayette, CO). Mouse bone marrow macrophages phagocytosed an average of 10 RBCs/macrophage in the average number of RBCs/cell or the percent of cells with ingested RBCs. There was no difference between wild-type and ffe/fte/macrophages in the average number of RBCs/cell or the percent of cells with ingested RBCs.

**Erythrophagocytosis**

Erythrophagocytosis was performed as described. Macrophages were incubated with IgG-coated red blood cells (RBCs) at a ratio of 20 RBCs/macroage for 90 minutes. The cultures were then washed free of extracellular RBCs and incubated for 18 hours before measurement of ferritin. Wild-type and ffe/ffe/macrophages phagocytosed an average of 10 RBCs/macroage with more than 95% of the cells containing RBCs. There was no difference between wild-type and ffe/ffe/macrophages in the average number of RBCs/cell or the percent of cells with ingested RBCs.

**siRNA transfection**

siRNA oligonucleotide pools, nonspecific and mouse Fpn specific, were obtained from Dharamcon (Layette, CO). Mouse bone marrow macrophages were transfected with siRNAs at concentrations up to 100 nM using Oligofectamine reagent (Invitrogen) as described. At 24 hours after transfection, the cells were trypsinized and plated onto 35-mm plates with or without ferric ammonium citrate (FAC) (10 μM Fe). Cells were grown for 18 hours and then processed for Western blot and ferritin analysis.

**Other procedures**

Immunofluorescence was performed as described previously. Fluorescent images were captured on an Olympus BX51 microscope (Olympus, Tokyo, Japan) using an Olympus U-Camd-Z camera and a 60X/1.3 NA oil-immersion objective lens. Images were acquired using Picture Frame 2.5 software (Olympus America, East Muskegon, OK). Captured images were combined in Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA) to generate multiple-image figures for publication. Fpn was detected using a rabbit anti-Fpn antibody (1:100; a generous gift from Dr David Haile). Transferrin receptor 1 was detected using a mouse anti-human transferrin receptor 1 antibody (CD81 1:100; RDI, Concord, MA) followed by Alexa 594–conjugated goat anti–rabbit IgG (1:750; Molecular Probes). Mouse anti-FLAG antibody M2 (Sigma, St Louis, MO) was used to detect Fpn-FLAG by immunofluorescence (1:750) followed by Alexa 594–conjugated goat anti–mouse IgG (1:750); Molecular Probes). Cellular protein was extracted with 150 mM NaCl, 10 mM EDTA, 10 mM Tris (pH 7.4), 1% Triton X-100, and a protease inhibitor cocktail (Roche, Indianapolis, IN). Western analysis was performed as described previously using rabbit anti-Fpn (1:500) and mouse anti–human α-tubulin (1:5000) followed by either peroxidase-conjugated goat anti–rabbit IgG (1:12 500; Jackson Immunoresearch Labs, West Grove, PA) or peroxidase-conjugated goat anti–mouse IgG (1:12 500; Jackson Immunoresearch Labs). Mice were bled retro-orbitally and peripheral blood smears were stained with Wright–Giemsa. Ferritin analysis was performed as described. Transferrin saturation was determined by means of a ferrozine-based iron and total iron-binding capacity assay (Teco Diagnostic, Anaheim, CA). Protein concentration was measured using the BCA assay (Pierce, Rockford, IL). All experiments were repeated a minimum of 3 times.

**Results**

The flatiron (ffe) mutation is in the Fpn gene

In a screen for recessive mutations induced by ethylnitrosourea that affect development of the mouse embryo, we identified ffe as a recessive mutation that causes developmental defects on a mixed C3H/HeJ X C57BL/6 background, including neural tube closure defects, microphthalmia, forebrain truncations, generalized edema, severe anemia, and mid-gestation lethality (data not shown). When the ffe mutation was crossed onto the 129/SvJ inbred strain, homozygous mutant embryos showed only severe anemia and mid-gestation lethality (Figure 1A-B). Using a positional cloning strategy, the ffe mutation was mapped to a 2.6-megabase interval on mouse chromosome 1 that contains 16 transcripts, including the Slc40a1 gene encoding the Fpn protein (Figure 1C). Fpn is the only exporter of cellular iron in mammalian cells and is expressed on placental syncytiotrophoblast cells where it is required for iron transport from the maternal circulation to the fetus. Sequencing of the cDNA encoding Fpn from ffe mutant embryos revealed a c.95A→G nucleotide substitution. The deduced amino acid substitution is H32R in the first putative transmembrane domain (Figure 1D). Most FpnH32R embryos die by E7.5 because of defects in iron transfer across the visceral endoderm, indicating that FpnH32R is a hypomorphic allele of Fpn. It is likely that the more complex phenotype seen in the original mutant was due to the background strain, as the complex phenotype was lost when the mice were bred onto different backgrounds.

**The ffe mutation results in mislocalization of Fpn**

The cell surface localization of Fpn is essential for its function, and the ffe mutation could result in mislocalization of Fpn, thus inhibiting iron transport into the fetal circulation. To determine if the FpnH32R mutation results in its mislocalization, this mutation (H32R) was introduced into a plasmid containing a green fluorescent protein (GFP)–tagged Fpn. As shown in Figure 2A, Fpn-GFP expressed in HEK-293T cells is localized to the plasma membrane. In contrast, Fpn(H32R)-GFP is predominantly intracellular. To determine if Fpn(H32R)-GFP has iron-exporting activity, cells expressing Fpn-GFP or Fpn(H32R)-GFP were iron loaded by incubation with ferric ammonium citrate (FAC), inducing the expression of the iron storage protein ferritin (Figure 2B). Expression of Fpn-GFP leads to iron export, resulting in decreased ferritin levels, whereas expression of Fpn(H32R)-GFP results in only a minor decrease in ferritin, indicating that the FpnH32R allele has significantly decreased iron-exporting activity.
We have shown that Fpn is a multimer and mutations in Fpn that affect cell surface localization also result in mislocalization of wild-type Fpn. To determine if expression of Fpn(H32R)-GFP can change the localization of the wild-type protein, Fpn-FLAG was coexpressed with Fpn-GFP or mutant Fpn(H32R)-GFP and localization of the tagged proteins was determined by immunofluorescence. Coexpression of Fpn-GFP with Fpn-FLAG resulted in plasma membrane localization of both proteins (Figure 2C). In contrast, coexpression of Fpn-GFP(F32R) with Fpn-FLAG resulted in the intracellular localization of GFP and FLAG-tagged proteins, indicating that mutant Fpn can change the localization of wild-type protein. This is specific to Fpn, as expression of Fpn(H32R)-GFP did not affect localization of transferrin receptor 1. To determine if mutant Fpn can affect the iron-exporting activity of wild-type Fpn, Fpn-FLAG was coexpressed with Fpn-GFP or Fpn(H32R)-GFP in iron-loaded HEK293T cells. Coexpression of wild-type proteins resulted in export of cellular iron and decreased ferritin levels (Figure 2D). Cells coexpressing Fpn(H32R)-GFP with Fpn-FLAG had elevated levels of ferritin, indicating that the Fpn(H32R) can act as a dominant negative by changing the localization of wild-type Fpn and its iron-exporting activity.

**Mutant Fpn(ffe)** acts as a dominant negative in macrophages isolated from **ffe/ffe** mice

To determine if endogenous levels of Fpn(ffe) also act as a dominant negative in vivo, macrophages were isolated from Fpn(ffe/ffe) heterozygous mice and localization of endogenous Fpn was examined. Expression of Fpn in macrophages is induced in response to high levels of cellular iron. Little Fpn is expressed in untreated primary cultures of macrophages isolated from wild-type or Fpn(ffe/ffe) animals (Figure 3A-B). Upon iron loading, high levels of Fpn are detected at the cell surface of wild-type macrophages. Iron loading of macrophages from Fpn(ffe/ffe) heterozygous mice did not result in expression of Fpn on the cell surface, although equivalent levels of Fpn were detected in wild-type and Fpn(ffe/ffe) macrophages (Figure 3B). Since Fpn(ffe/ffe) mice express both a wild-type and mutant allele of Fpn, these results indicate that Fpn(ffe) inhibits the cell surface localization of wild-type Fpn.

To determine if macrophages from Fpn(ffe/ffe) mice are able to export iron, macrophages from wild-type or Fpn(ffe/ffe) mice were loaded with iron and cellular ferritin levels were measured. Wild-type and Fpn(ffe/ffe) cells expressed equivalent amounts of ferritin in the absence or presence of FAC. Wild-type macrophages exported cellular iron upon removal of FAC, as indicated by decreased ferritin levels (Figure 3C, black bars); however, macrophages isolated from Fpn(ffe/ffe) mice were not able to efficiently export iron, and ferritin levels remained high (Figure 3C, gray bars). Similar results were obtained when macrophages were loaded with iron by engulfing RBCs, although the absolute level of ferritin was lower in RBC-fed macrophages (Figure 3C). Together these results indicate that Fpn(ffe) acts as a dominant negative in vivo by associating with wild-type Fpn, causing its mislocalization and thus preventing its ability to export iron.

It has been suggested that mutations in Fpn might result in cellular iron overload due to haploinsufficiency; however, mice that are heterozygous for a targeted gene deletion of Fpn do not show evidence of iron-overload disease. To further explore the possibility that haploinsufficiency could explain decreased iron export, we used RNAi to silence mouse Fpn in macrophages. Cells were transfected with nonspecific oligonucleotides or different concentrations of oligonucleotides specific to mouse Fpn. After 24 hours, cells were loaded with iron and levels of Fpn and cellular ferritin were determined 48 hours after transfection. Macrophages showed almost normal levels of iron export even when Fpn protein.
levels were decreased by 50% (Figure 3D). Reduction in iron-exporting activity (higher levels of ferritin) did not occur until Fpn levels decreased to below 30% of wild-type levels. These results indicate that half normal levels of Fpn, which would be expected in haploinsufficiency, cannot explain the defect in Fpn disease.

ffe/ffe mice have ferroportin disease

We sought to determine if expression of the dominant-negative Fpnffe allele in Fpnffe/+ heterozygous mice can mimic the human disease. In human patients, Fpn-linked hemochromatosis has a heterogeneous presentation. Some patients exhibit the classic symptoms of hemochromatosis, such as high transferrin saturation and iron accumulation in parenchymal cells. This presentation is associated with mutations in Fpn that affect its response to hepcidin. Other patients present with an early rise in ferritin levels, low to normal transferrin saturation, and iron accumulation primarily in Kupffer cells. This presentation is associated with mutations in Fpn that affect its plasma membrane localization or iron-exporting activity. Serum ferritin levels in Fpnffe/+ heterozygous animals were increased 10-fold over 6-month-old control animals and increased with age (Figure 4A). In addition, transferrin saturation in serum from 6-month-old heterozygotes was much lower than that of control mice (Figure 4B). Blood smears from 4-week-old wild-type animals showed normochromic and normocytic RBCs that have a uniform size and shape and no target cells (Figure 4C). Blood smears from 4-week-old Fpnffe/+ heterozygous animals revealed some hypochromic red blood cells with variable size and some target cells (Figure 4D). These results show that Fpnffe/+ animals have a mild anemia, which is consistent with the extremely low transferrin saturation. To determine if heterozygous animals also present with iron accumulation in Kupffer cells, Prussian Blue staining was used to visualize accumulated ferric iron. Livers from wild-type mice do not accumulate iron (Figure 4E) whereas livers from aged Fpnffe/+ animals accumulate high levels of iron in Kupffer cells (Figure 4F). Together, these results indicate that expression of the Fpnffe allele affects the ability of wild-type Fpn to export iron by inhibiting the localization and activity of wild-type Fpn. Furthermore, the close similarities between the clinical phenotypes of Fpnffe/+ mice and human patients demonstrates the utility of the Fpnffe/+ mouse as a model for this disease.

Discussion

Mutations in Fpn result in an autosomal-dominant disorder with 2 different patient presentations. Mutations that render Fpn insensitive to down-regulation by hepcidin result in iron overload in hepatocytes. In this form of the disorder there is no regulation of Fpn, leading to high transferrin saturation and iron deposition in hepatocytes. The iron burden of hepatocytes can be reduced by phlebotomy, as liver iron stores are capable of being mobilized through Fpn. A second class of Fpn mutations prevents localization to the cell surface or permits its localization to the cell surface but affects the ability of Fpn to transport iron. This form of the disorder, referred to as classic Fpn disease, results in low transferrin
The amount of ferritin in cells incubated with 50 nM to 100 nM Fpn-specific oligonucleotide pools was equivalent to that of untransfected cells. The error bars represent the standard deviation.

Bone marrow macrophages from wild-type mice were transfected with either nonspecific oligonucleotide pools or with different concentrations of oligonucleotide pools specific for mouse Fpn. Cells were incubated with FAC (10 nM Fe) for 24 hours or with IgG-coated RBCs for 90 minutes. Cells were washed and ferritin levels measured by ELISA after 16 hours (+/− refers to cells incubated with FAC and then incubated in the absence of FAC; black bars represent wild type; gray bars represent ffe/+). The error bars represent the standard deviation.

Bone marrow macrophages from wild-type mice were transfected with either nonspecific oligonucleotide pools or with different concentrations of oligonucleotide pools specific for mouse Fpn. Cells were incubated with FAC (10 nM Fe) for 24 hours and then in the absence of FAC for 16 hours. Cell extracts were isolated and assayed for ferritin by ELISA or for Fpn by Western blot analysis. The amount of Fpn in cells incubated with nonspecific oligonucleotides was identical to that of cells not transfected and was taken as 100%. The Western blots were analyzed by densitometry and Fpn was normalized to α-tubulin.

The amount of ferritin in cells incubated with 50 nM to 100 nM Fpn-specific oligonucleotide pools was equivalent to that of untransfected cells. The error bars represent the standard deviation.

Figure 3. Localization of Fpn and iron transport activity in macrophages from ffe+/− mice. (A,B) Bone marrow macrophages isolated from wild-type mice or ffe+/− mice were incubated in the presence or absence of FAC (10 μM Fe) for 24 hours. The localization of Fpn was analyzed by immunofluorescence using an antibody to Fpn and the amount of Fpn was determined by Western analysis using an antibody to α-tubulin as a loading control. The arrows denote intracellular localization. The arrowheads denote intracellular localization. (C) Cells were incubated with or without FAC (10 μM Fe) for 24 hours or with IgG-coated RBCs for 90 minutes. Cells were washed and ferritin levels measured by ELISA after 16 hours (+/− refers to cells incubated with FAC and then incubated in the absence of FAC; black bars represent wild type; gray bars represent ffe/+). The error bars represent the standard deviation. (D) Bone marrow macrophages from wild-type mice were transfected with either nonspecific oligonucleotide pools or with different concentrations of oligonucleotide pools specific for mouse Fpn. Cells were incubated with FAC (10 μM Fe) for 24 hours and then in the absence of FAC for 16 hours. Cell extracts were isolated and assayed for ferritin by ELISA or for Fpn by Western blot analysis. The amount of Fpn in cells incubated with nonspecific oligonucleotides was identical to that of cells not transfected and was taken as 100%. The Western blots were analyzed by densitometry and Fpn was normalized to α-tubulin.

The amount of ferritin in cells incubated with 50 nM to 100 nM Fpn-specific oligonucleotide pools was equivalent to that of untransfected cells. The error bars represent the standard deviation.

The discovery of the ffe mutation shows that mice can have Fpn disease, as mice heterozygous for the mutation exhibit all of the features of the human disorder: low transferrin saturation, high serum ferritin, and excessive iron deposits in Kupffer cells, not hepatocytes. Patients with these types of Fpn mutations develop severe anemia upon repeated phlebotomy and iron stores in liver are not mobilized because mutant Fpn cannot export the excess iron. It has been a source of debate whether haploinsufficiency would explain Fpn disease or whether the disease results from a dominant-negative effect. While studies have supported the view that Fpn is a multimer,9,13,24 and that the mutant allele can affect the behavior of the wild-type allele, other studies have suggested that Fpn is monomeric.10,12,25 All human Fpn mutations are missense mutations. If haploinsufficiency was the explanation for Fpn disease, then nonsense mutations should also result in the disorder; however, none have been found. Additionally, a targeted gene deletion in the murine Fpn gene has little effect in heterozygous animals.14 While these data suggest that haploinsufficiency cannot explain the disorder it is formally possible that Fpn disease in mice cannot recapitulate the human disease.

Acknowledgments

The authors wish to express their appreciation to Dr Richard Ajioka for help in measuring transferrin saturation; Kathryn V. Anderson and members of the Anderson and Niswander laboratories for performing the mutagenesis screen; Lori Bulwith for technical assistance; and Christopher Porter for help with blood smears. The current address for I.E.Z. is Center for Neuroscience Research, Children’s Research Institute, Children’s National Medical Center, Washington, DC.

This work was supported by National Institutes of Health (NIH) grants DK070 947 (J.K.) and F32-HD08 605 (I.E.Z.). J.F.G. is
supported by an NIH training grant (T32CA8608604). L.N. is a Howard Hughes Medical Institute (HHMI) investigator.

**Authorship**

Contribution: I.E.Z. performed the positional cloning, preparation of mouse samples for further analysis, histologic analysis, and wrote the manuscript; I.D.D. generated the Fpn(H32R)-GFP plasmid, performed the immunofluorescence, macrophage culturing, ferritin analysis, and transferrin saturation analysis, and wrote the manuscript; A.P. performed the positional cloning, sequencing of the ffe mutation, and histologic analysis; D.M.W. performed the immunofluorescence and assisted in the writing and preparation of the manuscript; A.J.S. performed the positional cloning; J.F.G. and X.L. analyzed the peripheral blood smears; and L.N. and J.K. guided these studies and assisted in manuscript preparation.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

I.E.Z. and I.D.D. contributed equally to this work.

Correspondence: Jerry Kaplan, Department of Pathology, School of Medicine, University of Utah, Salt Lake City, UT 84132; e-mail: jerry.kaplan@path.utah.edu.

**References**


Erratum

In the article by Papadaki et al entitled “Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect,” which appeared in the March 1, 2002, issue of Blood (Volume 99:1610-1619), Figure 1 depicts the mode of data analysis from a representative healthy control. Due to an oversight, this figure is similar to Figure 1 of the article by Papadaki et al entitled “Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus” published in the October 2001 issue of British Journal of Haematology (Volume 115:167-174). Although this does not affect any of the data or conclusions of the papers, Dr Papadaki, as corresponding and senior author of both papers, wishes to replace Figure 1 in Blood 2002;99:1610-1619 with the figure below derived from the cohort of the healthy controls used in the Blood study. Dr Papadaki apologizes to Blood and British Journal of Haematology editorial staff and readers for this oversight.
The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease

Irene E. Zohn, Ivana De Domenico, Andrew Pollock, Diane McVey Ward, Jessica F. Goodman, Xiayun Liang, Amaru J. Sanchez, Lee Niswander and Jerry Kaplan

Updated information and services can be found at:
http://www.bloodjournal.org/content/109/10/4174.full.html

Articles on similar topics can be found in the following Blood collections
- Free Research Articles (4447 articles)
- Hematopoiesis and Stem Cells (3419 articles)
- Red Cells (1159 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml